EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictors of in vitro response to somatostatin and dopamine receptor‐targeted treatments are lacking in clinically non‐functioning pituitary tumors

Claudia Campana iD, Jessica Amarù iD, Diego Criminelli Rossi iD, Anna Arecco iD, Paolo Nozza, Mara Boschetti iD, Gianluigi Zona iD, Diego Ferone iD, Marica Arvigo iD, Federico Gatto iD

Journal of Neuroendocrinology · 2026-10 · 38 (10)

DOI: 10.1111/jne.70272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 24.09.2026. Verfasst von Claudia Campana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), School of Medical and Pharmaceutical Sciences, University of Geno…. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Receptors, Somatostatin, Somatostatin, Dopamine Agonists. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinically non‐functioning pituitary neuroendocrine tumors (NF‐PitNETs) lack effective medical therapies, and the role of somatostatin receptor ligands (SRLs) and dopamine agonists (DAs) in this setting is controversial. We evaluated the in vitro response of NF‐PitNETs to multiple SRL and/or DA treatments, focusing on the role of receptor expression and tumor characteristics in driving tumor response. Forty‐four NF‐PitNET primary cultures were treated (72 h, 10 nM) with octreotide (OCT), pasireotide (PAS), OCT + PAS, BIM‐53097 (D2R agonist), BIM‐53097 + PAS, and BIM‐23B065 (SSTR2/SSTR5/D2R preferential ligand) to evaluate cell proliferation inhibition. Tumors were considered responders to a treatment when a ≥20% reduction in cell proliferation was observed (vs. control); responder tumors to at least one tested condition were classified into the “responder group” for further analysis. Somatostatin (SSTRs) and dopamine type 2 receptor (D2R) expression were evaluated through immunohistochemistry. Data on radiological invasiveness, proliferation indices (Ki67%, mitoses), and p53 immunostaining were collected. Tumor grade was determined using Trouillas and PANOMEN‐3 classifications. Median patient age at surgery was 60.3 years (IQR 49.7–70.7), 29 were males (71%). Overall, no significant in vitro inhibition of cell proliferation was observed [ranging from −4.2% (OCT and PAS) to −7.4% (BIM‐53097 + PAS)]. However, 13 cultures (30%) were included in the “responder group” [mean inhibition ranging from −18.6% (OCT) to −27.7% (BIM‐53097 + PAS)]. D2R was the most expressed receptor (median IRS 8, IQR 6–8), followed by SSTR1 and SSTR2 (median IRS 4, IQR 3–6); SSTR3 and SSTR5 expression was low. In the whole cohort, OCT and PAS efficacy directly correlated with SSTR2 ( p = .013 and p = .027, respectively). D2R and SSTR2 expression was higher in responders vs. non‐responders to BIM‐23B065 ( p = .017 and p = .042, respectively). ROC curve analysis discriminates BIM‐23B065 responders based on D2R and SSTR2 expression with acceptable ability (AUC = 0.784 and AUC = 0.743, respectively). However, the “responder group” did not differ significantly from the “non‐responder group” with respect to patient demographics, tumor clinical–pathological characteristics, receptor expression, and grading. In conclusion, we confirm the limited efficacy of SRL and DA treatment in NF‐PitNETs. D2R and SSTR2 can discriminate tumors responsive to BIM‐23B065. As concerns the other tested compounds, none of the tumor parameters evaluated demonstrated robust predictive value for NF‐PitNET in vitro response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsReceptors, SomatostatinSomatostatinDopamine AgonistsReceptors, Dopamine D2Neuroendocrine TumorsHumansCell ProliferationMaleFemaleOctreotideMiddle AgedTumor Cells, CulturedReceptors, DopamineDopamine

Stichwörter der Autor:innen

chimeric moleculesdopamine receptormedical treatmentnon‐functioning pituitary tumorsomatostatin receptor

Substanzen

Receptors, SomatostatinSomatostatinOctreotidepasireotideDopamine AgonistsReceptors, Dopamine D2BIM 23206TBR-760Receptors, DopamineDopamine

Autor:innen und Institutionen

  • Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), School of Medical and Pharmaceutical Sciences, University of Genova, Genoa, Italy.
  • Department of Neurosurgery, IRCCS AOM - Policlinico San Martino, Genoa, Italy.
  • Pathology Unit, IRCCS AOM - Policlinico San Martino, Genoa, Italy.
  • Endocrinology Unit, IRCCS AOM - Policlinico San Martino, Genoa, Italy.
  • Neurosurgery Unit, Department of Neuroscience, Ophthalmology, Genetics and Childhood and Maternal sciences (DiNOGMI), University of Genova, Genoa, Italy.

ORCID-Profile: Claudia Campana, Jessica Amarù, Diego Criminelli Rossi, Anna Arecco, Mara Boschetti, Gianluigi Zona, Diego Ferone, Marica Arvigo, Federico Gatto

Zitieren

APA

Campana, C., Amarù, J., Rossi, D. C., Arecco, A., Nozza, P., Boschetti, M., Zona, G., Ferone, D., Arvigo, M., & Gatto, F. (2026). Predictors of in vitro response to somatostatin and dopamine receptor‐targeted treatments are lacking in clinically non‐functioning pituitary tumors. Journal of Neuroendocrinology, 38(10). https://doi.org/10.1111/jne.70272

Vancouver

Campana C, Amarù J, Rossi DC, Arecco A, Nozza P, Boschetti M, et al. Predictors of in vitro response to somatostatin and dopamine receptor‐targeted treatments are lacking in clinically non‐functioning pituitary tumors. Journal of Neuroendocrinology. 2026;38(10). doi:10.1111/jne.70272

BibTeX
@article{Campana2026,
  author = {Campana, Claudia and Amarù, Jessica and Rossi, Diego Criminelli and Arecco, Anna and Nozza, Paolo and Boschetti, Mara and Zona, Gianluigi and Ferone, Diego and Arvigo, Marica and Gatto, Federico},
  title = {Predictors of in vitro response to somatostatin and dopamine receptor‐targeted treatments are lacking in clinically non‐functioning pituitary tumors},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  volume = {38},
  number = {10},
  doi = {10.1111/jne.70272}
}
Kostenlos starten →